

## PATIENT INFORMATION

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_ Sex: M F Ht: \_\_\_\_\_ Wt: \_\_\_\_\_ lbs kg  
Primary Language: \_\_\_\_\_ Allergies: \_\_\_\_\_  
Patient Preferred Location: \_\_\_\_\_

<ICD 10 CODE REQUIRED>

## DIAGNOSIS & CLINICAL INFORMATION

### ICD 10 Code

- K50.0 \_\_\_\_\_ Crohn's Disease, Small Intestine
- K50.1 \_\_\_\_\_ Crohn's Disease, Large Intestine
- K50.8 \_\_\_\_\_ Crohn's Disease, Small and Large Intestine
- K50.9 \_\_\_\_\_ Crohn's Disease, Unspecified

**REQUIRED:** Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.  
**LAB RESULTS:** Include Negative TB within 12 months.

## PRESCRIPTION

### SKYRIZI IV (risankizumab-rzaa)

#### Loading Dose IV

Infuse 600 mg in 250 ml of 5% Dextrose over at least 1 hour at weeks 0, 4, and 8

### Lab Orders+

Required: Negative TB, Liver enzymes and bilirubin at weeks 0 and 4

**+Medix Infusion will draw maintenance labs unless otherwise directed by Referring Provider**

Is the patient on any other disease modifying therapy? Yes No  
If yes, please note therapy and last dose: \_\_\_\_\_

**Post Treatment Observations:** The patient is observed for 30 minutes following the first administration.

**Adverse Events:** In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.

### Comments:

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

## PRESCRIBER INFORMATION

Prescriber Name: \_\_\_\_\_ Signature: \_\_\_\_\_  
Date: \_\_\_\_\_ NPI #: \_\_\_\_\_ Specialty: \_\_\_\_\_  
Supervising Physician: \_\_\_\_\_ (If Applicable)  
Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_